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The androgen receptor (AR), a member of the subfamily of steroid
receptors, has a pivotal role in the regulation of prostate growth
and secretory responses. After binding of its ligand, the AR under-
goes a conformational change and acquires an active form which
regulates transcription of androgen-responsive genes (Kallio et al,
1994). Thereby its functional activity is modulated by interactions
with receptor-associated tissue-specific co-regulatory proteins,
called co-activators and co-repressors (Ikonen et al, 1994; Yeh and
Chang, 1996; Froesch et al, 1998). AR mRNA and protein in the
prostate are differentially regulated by androgens; androgen treat-
ment leads to down-regulation of AR mRNA but stabilizes the
protein (Krongrad et al, 1991; Zhou et al, 1995). In consequence,
stabilization of AR protein results in a net increase in AR expres-
sion. The regulation of mRNA for the AR is, however, cell-type
specific. In contrast to prostatic tissue, AR mRNA in bone cells is
up-regulated by androgen (Wiren et al, 1997). In addition to andro-
genic hormones, some polypeptide growth factors, cytokines and
compounds that increase intracellular cAMP levels participate in
the regulation of AR expression. Epidermal growth factor (EGF)
decreases the levels of AR mRNA as well as AR protein in the
human prostatic carcinoma cell line LNCaP (Mizokami et al,
1992; Henttu and Vihko, 1993). Moreover, it was shown that inter-
leukin-1b (IL-1b), which is present in conditioned medium from
peripheral blood monocytes, is responsible for down-regulation of
AR protein expression (Culig et al, 1998). AR protein levels were
also found to be reduced in response to retinoic acid (Young et al,
1994). In contrast, cAMP increases AR expression at the transcrip-
tional level and cAMP response element was described in the
human AR gene promoter (Mizokami et al, 1994).
Until now, effects of basic fibroblast growth factor (bFGF) on
AR protein expression in prostate cancer have not been studied.
bFGF is a multifunctional peptide that is the prototype of heparin-
binding growth factors (Bikfalvi, 1995). Studies from our labora-
tory and others showed higher bFGF serum levels in patients with
carcinoma of the prostate compared with healthy controls (Meyer
et al, 1995; Cronauer et al, 1997a). In some cases, prostate tumour
progression is associated with an increase in serum bFGF
(Cronauer et al, 1997a). bFGF itself is expressed in prostate cancer
cells and in tissue specimens (Nakamoto et al, 1992; Cronauer et
al, 1997a). AR expression was unequivocally demonstrated in all
histological types of prostate cancer and in metastatic lesions (Van
der Kwast et al, 1991; Hobisch et al, 1995, 1996). Previous work
revealed negative effects of bFGF on AR-regulated prostate-
specific antigen (PSA) transcripts in LNCaP cells (Gleave et al,
1992). Based on that study, we asked whether bFGF effects on
PSA may be due to down-regulation of expression of the AR.
LNCaP cells were derived from a lymph node metastasis from
human carcinoma of the prostate and express high amounts of the
mutated AR, that is activated by various steroid hormones and
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present report, we have investigated the regulation of AR protein
and mRNA expression by bFGF in LNCaP cells.
MATERIALS AND METHODS
Materials
The human prostate tumour cell line LNCaP was purchased from
the American Type Culture Collection (Rockville, MD, USA).
MCDB-131 medium, dihydrotestosterone (DHT) and calcium
ionophore A 23187 were from Sigma (St Louis, MO, USA). Fetal
calf serum (FCS) was purchased from Biological Industries
(Kibbutz Beth Haemek, Israel). Trypsin–EDTA was from
HyClone (Cramlington, UK). Phosphate-buffered saline (PBS)
was obtained from PAA Laboratories (Linz, Austria). Cell culture
plasticware was from Falcon (Lincoln, NE, USA), Costar
(Cambridge, MA, USA) and Sarstedt (Nürmbrecht, Germany).
bFGF was purchased from Biomol (Hamburg, Germany).
AR-specific rabbit antiserum PG-21 was from Paesel-Lorei
(Frankfurt/M, Germany) and peroxidase-labelled mouse anti-
rabbit immunoglobulin was a product of Santa Cruz
Biotechnologies (Santa Cruz, CA, USA). Western blotting detec-
tion reagents were from Amersham (Little Chalfont, UK).
Unlabelled and 3H-labelled methyltrienolone (R1881) were
purchased from New England Nuclear (Dreieichenhain,
Germany). Fura-2 was obtained from Molecular Probes (Eugene,
OR, USA).
Cell culture
LNCaP cells were grown at 37°C in a humidified atmosphere of
5% carbon dioxide in air. The cells were routinely cultured in
MCDB-131 supplemented with 5% FCS, penicillin (120 mg ml–1)
and streptomycin (120 U ml–1). In all experiments, 5% charcoal-
stripped (CS) FCS was used.
Determination of prostate-specific antigen in the
supernatants of LNCaP cells
LNCaP cells were seeded into 24-well plates and allowed to
adhere for 24 h. Then they were cultured for 24, 48 and 72 h
respectively, with DHT in the absence or presence of increasing
concentrations of bFGF. Afterward, the medium was removed and
PSA was assessed by a microparticle enzyme immunoassay IMx
(Abbott Laboratories, Abbott Park, IL, USA). The sensitivity of
the assay was calculated to be 0.02 ng ml–1. PSA levels were
normalized according to cell numbers which were determined
using a coulter counter (Coulter Electronics, Harpenden, Herts,
UK).
Immunoblotting of the androgen receptor
LNCaP cells were plated in 6-well culture dishes and cultured in
the absence or presence of bFGF. DHT was added into culture
media because (i) the experiments were carried out under the same
conditions as PSA measurements and (ii) previous reports demon-
strated positive effect of DHT on AR stabilization (Krongrad et al,
1991; Zhou et al, 1995). Cell monolayers were detached by
trypsinization. Cell pellets were harvested by centrifugation in a
tabletop centrifuge (3 min, 1500 g). They were resuspended in a
phosphate buffer (pH 7.5, 20 mM NaH2PO4, 1 mM EDTA, 10%
glycerol and 0.1% monothioglycerol) and homogenized with an
ultrasound disintegrator Sonifier 250 (Branson, Danburry, CT,
USA). Protein concentration in homogenates was measured by the
method of Bradford (1978). Equal amounts of protein from each
sample were separated by sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis on a 8%-gel and transferred to the
membranes. Non-specific binding was blocked by incubating
the membrane with 5% non-fat dry milk in PBS. Afterward,
the membrane was exposed to the AR-specific antiserum PG-21
(dilution 1:500) for 2 h at room temperature. After 3 washing
cycles, the immunocomplex was detected by incubating the
membrane with peroxidase-labelled mouse anti-rabbit
immunoglobulin for another 2 h. AR bands were visualized by
enhanced chemiluminescence.
AR binding studies
After incubation with either bFGF or the calcium ionophore A
23187, LNCaP cells were harvested, washed once and resus-
pended in MCDB-131 supplemented with 5% CS FCS. In order to
determine specific binding of the non-metabolizable androgen
R1881, the cells were subsequently incubated with increasing
concentrations of 3H-labelled R1881. Non-specific binding was
measured in the presence of a 200-fold molar excess of unlabelled
R1881. After 90 min incubation, cell pellets were recovered by
centrifugation (3 min, 3800 g) and washed twice in ice-cold
medium. Afterward, cell pellets were lysed in a scintillation liquid
Optiphase and radioactivity was determined in a b-scintillation
counter Wallac 1410 (Pharmacia, Turku, Finland). Bmax and Kd
were calculated by means of Scatchard analysis.
Measurement of intracellular calcium concentrations
Calcium release from intracellular stores and store-operated
calcium influx after treatment with the calcium ionophore A
23187 or bFGF were measured by single cell fluorescence tech-
nique employing fura-2 as previously described (Grynkiewicz
et al, 1985; Tinhofer et al, 1996). Cells were grown on sterile slide
covers for 24 h and labelled with 1 mM fura-2 for 30 min.
Afterward, the cells were washed with HBS (140 mM sodium
chloride (NaCl), 5 mM potassium chloride (KCl), 1 mM calcium
chloride (CaCl2), 0.5 mM magnesium chloride (MgCl2), 5.5 mM
glucose) for at least 30 min at room temperature. For determina-
tion of the cytoplasmic calcium concentration, the slide was placed
into the recording chamber and the cells were kept further in HBS.
The intracellular calcium concentration after treatment was calcu-
lated from the ratios of background subtracted images (excitation
wavelength 340 and 380 nm, emission wavelength 510 nm)
according to the calibration procedure described elsewhere
(Grynkiewicz et al, 1985).
Determination of androgen receptor mRNA levels by
semiquantitative RT-PCR
Cell pellets were obtained after incubation of LNCaP cells with
serum only, DHT, bFGF and a combination thereof respectively.
Total RNA was extracted from cell pellets using a guanidinium
thiocyanate–acid phenol–chlorophorm (pH 4.0) extraction tech-
nique (Eder et al, 1997). Reverse transcription was performed with
500 ng of RNA in 40 ml containing finnzyme buffer [20 mM
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Triton X-100, 5% glycerol], 0.5 mM dNTPs, 200 pmol N6-primers,
0.15%  b-mercaptoethanol, 0.1 mg ml–1 bovine serum albumin,
39 U ribonuclease inhibitor and 10 U finnzyme AMV reverse
transcriptase in a thermocycler. Thermocycler settings were as
follows: 8 min at 20°C, 8 min at 25°C and 30 min at 42°C
(4 cycles). Polymerase chain reaction (PCR) was performed with
2 ml of cDNA solution in a final volume of 50 ml PCR reaction
buffer (10 mM Tris–HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl,
0.1% Triton X-100) containing 0.1 mM of each dNTP, 1.25 U of
Dynazyme polymerase and 12.5 pmol of each primer. An AR
cDNA fragment and a cDNA fragment of the housekeeping gene
b2-microglobulin were amplified in a duplex PCR. Amplification
was started with AR primers alone for 4 cycles. Thereafter,
b2-microglobulin primers were added and the amplification was
continued for another 20 cycles. The thermocycler programme
used was as follows: a precycle of 3 min at 95°C followed by 24
cycles of 25 s at 94°C, 10 s at 96°C, 1 min at 57°C, 30 s at 73°C
and a postcycle of 2 min at 73°C. The primers used for AR detec-
tion were AR 2047/20 sense 5¢-ATG GTG AGC AGA GTG CCC
TA-3¢ (fluorescence-labelled) and 2474/21 antisense 5¢-GTG GTG
CTG GAA GCC TCT CCT-3¢. The primers used for the amplifica-
tion of b2-microglobulin were sense 5¢-ATG CCT GCC GTG
TGA ACC ATG T-3¢ and antisense 5¢-AGA GCT ACC TGT GGA
GCA ACC T-3¢ (fluorescence-labelled). After PCR amplification,
the samples were diluted in formamide, the fragments were sepa-
rated on a polyacrylamide sequencing gel on an ABI 370A DNA
sequencer (ABI, Foster City, CA, USA) and the fluorescence
intensities of both fragments were measured using the ABI
GeneScan Software. Results are expressed as an AR/b2-
microglobulin ratio.
Statistical analysis
Probability values were calculated by Mann–Whitney U-test.
P-values < 0.05 were considered statistically significant.
RESULTS
Effects of bFGF on PSA protein in LNCaP cells
PSA was determined in supernatants from LNCaP cells which
were cultured with bFGF in the presence of DHT (Figure 1 A–C).
bFGF down-regulated PSA protein in LNCaP cells in a dose-
dependent manner, consistent with previous observations made by
Gleave and associates (Gleave et al, 1992). This down-regulation
was observed after 24, 48 and 72 h of treatment respectively
(Figure 1 A–C). With 50 ng ml–1 bFGF, an 80% inhibition in PSA
protein expression was observed (Figure 1B). Based on these find-
ings, we investigated whether the inhibition of PSA protein is
preceded by negative effects of bFGF on AR expression.
Regulation of AR protein expression by bFGF
AR protein expression in LNCaP cells after treatment with bFGF
was studied by Western blotting and a radioligand binding assay.
When cells were grown in the presence of DHT AR was down-
regulated by bFGF, as revealed by Western blotting (Figure 2).
bFGF action was concentration-dependent. The lowest AR level
was observed after treatment with 50 ng ml–1 of bFGF. This
finding was confirmed by measurement of specific binding of
bFGF and androgen receptor expression 41
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Figure 1 Down-regulation of PSA protein secretion in LNCaP cells by
bFGF. The cells were incubated in the presence of 10 nM of DHT with
increasing concentrations of bFGF for (A) 24, (B) 48 and (C) 72 h. PSA
levels in the supernatants were measured by an enzyme immunoassay and
normalized according to cell numbers. Mean values were calculated from
three experiments; bars, s.e.m.; *P < 0.05, bFGF treatment vs untreated
control, Mann–Whitney U-test3H-labelled R1881 (data not shown). Binding studies showed also
a down-regulation of AR when cells were treated with bFGF in the
absence of DHT (Figure 3). Taken together, these results indicate
that down-regulation of AR by bFGF does not depend on the pres-
ence of DHT. Subsequently, we analysed time-course of the bFGF
effect by measurement of androgen binding after treatment with
bFGF for 8, 24 and 48 h (Figure 4). AR protein expression
decreased already after 8 h of treatment and a maximal inhibition
was observed 24 h after addition of bFGF to culture media.
Analysis of calcium release induced by bFGF
In LNCaP cells, an elevation of intracellular calcium levels was
shown to be associated with a decrease in AR mRNA and protein
(Gong et al, 1995). The ability of the calcium ionophore A 23187
to down-regulate AR expression was confirmed in our experi-
ments. AR protein level was reduced by 40% after 14 h treatment
with 1 mM of A 23187 (data not shown). bFGF is known to
increase calcium influx in several cell types (Cheng et al, 1993;
Merle et al, 1997). Therefore, the possibility that bFGF action on
AR expression is mediated by an elevation of intracellular calcium
levels was examined. As shown in Figure 5, A 23187 was able to
induce calcium influx and an increase in cytoplasmic calcium
concentration in LNCaP cells whereas bFGF was incapable of
eliciting a similar effect. We concluded that bFGF does not regu-
late AR protein by modulating intracellular calcium levels.
Analysis of AR mRNA levels
In order to investigate how bFGF affects AR mRNA, LNCaP cells
were treated with bFGF for 24 h and AR mRNA was determined
42 MV Cronauer et al
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Figure 2 Immunoblot analysis of AR protein expression. LNCaP cells were
cultured for 72 h in the absence (lane a) or presence of DHT (lanes b–d) with
bFGF at concentrations of 25 (lane c) or 50 ng ml–1 (lane d). Equal amounts
of protein from each sample were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis. Immunodetection was performed with the
anti-AR antibody PG-21 as described in Materials and Methods. This figure is
a representative of three experiments
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Figure 3 Specific androgen binding in bFGF-treated LNCaP cells. LNCaP
cells were cultured in the absence (control) or presence of bFGF (10 ng ml–1)
in the absence of DHT for 24 h. Subsequently, the cells were scraped off and
incubated for 90 min at room temperature with increasing concentrations of
3H-R1881. Nonspecific binding was measured in the presence of a 200-fold
molar excess of unlabelled R1881. After incubation, the cells were washed
twice in ice-cold medium and specific binding was determined. Bmax and Kd
were calculated by Scatchard analysis. (¡) Control, Kd = 1.4 nmol, Bmax =
0.80 fmol µg–1 protein; (¤) 10 ng ml–1 bFGF, Kd = 1.8 nmol, Bmax =
0.25 fmol µg–1 protein
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Figure 4 Time course of bFGF effect on AR expression. LNCaP cells were
treated with 10 ng ml–1 bFGF in the absence of DHT for 8, 24 and 48 h and
specific binding was determined as described in the legend for Figure 3. Two
experiments were performed. Bmax at each time point is expressed as percent
of Bmax measured in untreated cells
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Figure 5 Measurement of intracellular calcium concentrations by single cell
fluorescence technique in LNCaP cells. The cells were grown on sterile slide
covers and labelled with fura-2. They were treated with either calcium
ionophore A 23187 or bFGF in the absence of DHT. The measurement was
performed as described elsewhere (Grynkiewicz et al, 1985)by semiquantitative reverse transcription PCR (RT-PCR).
Treatment with DHT alone led to the down-regulation of AR
mRNA by 61% compared to untreated cells (Figure 6A). After
treatment with DHT and bFGF, AR mRNA did not decrease
further. The mean AR/b2-microglobulin ratio in cells treated with
DHT and bFGF was 0.7 ± 0.03, whereas the cells incubated with
DHT only had an AR/b2-microglobulin ratio of 0.78 ± 0.13. The
measurement of AR mRNA was also performed in LNCaP cells
treated with bFGF in the absence of DHT. There was no difference
between AR mRNA levels in cells treated with bFGF compared to
untreated controls (Figure 6B). Taken together, the results of these
experiments show that bFGF does not affect steady-state levels of
AR mRNA.
DISCUSSION
In the present study, we show that AR protein in human prostate
cancer cells is down-regulated by bFGF. This down-regulation
precedes the decrease in PSA protein measured in LNCaP super-
natants. Negative regulation of AR expression by a growth factor
was previously reported for EGF (Mizokami et al, 1992; Henttu
and Vihko, 1993). It seems, however, that bFGF and EGF modu-
late AR expression by different mechanisms because bFGF, in
contrast to EGF, does not diminish AR mRNA levels. We hypoth-
esize that bFGF action is exerted through degradation of the
receptor protein. An opposite effect, stabilization of AR protein by
androgen was previously demonstrated by Zhou and associates
(Zhou et al, 1995). Our observation that bFGF does not reduce AR
mRNA levels is supported by a recent paper by Russell and associ-
ates (1999). Those authors did not observe differences in AR
mRNA levels between LNCaP cells stably transfected with the
bFGF expression vector and the parental LNCaP cells.
Interestingly, bFGF-transfected cells showed a reduced growth
rate in response to androgen. This may be due to down-regulation
of AR protein by bFGF.
An elevation of intracellular calcium is implicated in down-
regulation of the AR in LNCaP cells (Gong et al, 1995). bFGF is
known to increase intracellular calcium levels in various cell
systems (Cheng et al, 1993; Merle et al, 1997). Therefore, we
initially hypothesized that this mechanism is operative in prostate
cancer cells. To verify this hypothesis, we applied an established
single cell fluorescence method to determine calcium levels.
However, we did not measure an increase in intracellular calcium
levels following bFGF treatment. Interestingly, Wasilenko and
associates recently reported that neither of the calcium agonists
tested was able to induce an elevation of intracellular calcium in
LNCaP cells (Wasilenko et al, 1997). Thus, other signalling path-
ways must be considered for inhibition of AR expression by bFGF.
bFGF regulates cellular growth and differentiation by involving
protein kinase C (Hrzenjak and Shain, 1997), mitogen-activated
protein kinase (Hurley et al, 1996; Milasincic et al, 1996), phos-
phatidylinositol 3-kinase (Raffioni and Bradshaw, 1992) or phos-
pholipase signalling (Sa and Fox, 1994; Suzuki et al, 1996).
bFGF was identified as a major autocrine growth factor
produced by prostate fibroblasts (Story et al, 1989). In later
studies, it was demonstrated that prostate epithelial cells are also a
source of bFGF (Nakamoto et al, 1992; Sherwood et al, 1992;
Cronauer et al, 1997a). The receptors for bFGF are expressed in
both mesenchymal and epithelial prostate cells (Nakamoto et al,
1992; Sherwood et al, 1992). Some observations from in vitro
studies support the view that down-regulation of the AR by bFGF
may be relevant to prostate cancer model systems. In the bFGF-
producing prostate cancer cell lines PC-3 and DU-145 as well as in
prostatic primary tissue cultures the AR is down-regulated (Tilley
et al, 1990; Grant et al, 1996). Nearly all media for primary
prostate cultures contain bovine pituitary extract that is a rich
source of bFGF (Chaproniere and McKeehan, 1986; Peehl and
Stamey, 1986; Baird and Böhlen, 1991; Cronauer et al, 1997b).
This fact may provide a partial explanation for an absent or very
low expression of the AR in primary cultures of prostatic epithelial
cells. Conversely, androgen-sensitive LNCaP cells did not express
bFGF (Cronauer et al, 1997a).
Data on bFGF expression in prostate cancer clinical specimens
are scarce. However, we reported that in a limited number of
specimens an increased bFGF expression was associated with
a more advanced tumour stage (Cronauer et al, 1997a).
Immunohistochemical studies utilizing double staining for bFGF
and the AR in prostate tumour specimens might be helpful for
understanding implications of AR regulation by bFGF in vivo.
bFGF and androgen receptor expression 43
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Figure 6 Measurement of AR mRNA levels in LNCaP cells by
semiquantitative RT-PCR. AR mRNA levels were determined after treatment
with (A) DHT (10 nM) or DHT and bFGF (50 ng ml–1) and (B) bFGF for 24 h.
mRNA levels are expressed as an AR/b2-microglobulin ratio. Three
independent experiments were performed and mean values were calculated;
bars, s.e.m.It became clear that the AR is expressed in all prostate tumours
even in those that do not respond to endocrine therapy and that
currently available anti-androgens may enhance AR activity in
advanced carcinoma of the prostate (Van der Kwast et al, 1991;
Hobisch et al, 1995, 1996; Peterziel et al, 1995). Identification of
signalling cascades which are responsible for AR down-regulation
by bFGF might therefore be useful for development of new
approaches to control advanced carcinoma of the prostate by
modulation of AR levels.
In contrast to IL-1b and retinoic acid that down-regulate the AR
and inhibit cellular proliferation, bFGF stimulates the proliferation
of LNCaP cells (Nakamoto et al, 1992; Young et al, 1994;
Cronauer et al, 1997a; Culig et al, 1998). Application of bFGF
antisense oligonucleotides in rat prostate tumours led to inhibition
of cell growth (Shain et al, 1996). Taken together, these findings
indicate that AR content is only one determinant of mitogenic
potential of prostate carcinoma cells.
In summary, our studies show that bFGF is a potent negative
regulator of AR protein level in the human prostate cancer cell line
LNCaP. The underlying molecular mechanisms remain to be
elucidated in future studies.
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